These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25092460)

  • 21. Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels.
    He Y; Huang M; Tang C; Yue Y; Liu X; Zheng Z; Dong H; Liu D
    Virus Res; 2021 Jun; 298():198404. PubMed ID: 33775754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin.
    Zhao LJ; Wang W; Liu Y; Ren H; Qi ZT
    Antiviral Res; 2012 Nov; 96(2):260-8. PubMed ID: 22985631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model.
    Umehara T; Sudoh M; Yasui F; Matsuda C; Hayashi Y; Chayama K; Kohara M
    Biochem Biophys Res Commun; 2006 Jul; 346(1):67-73. PubMed ID: 16750511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication.
    Rance E; Tanner JE; Alfieri C
    J Viral Hepat; 2012 Feb; 19(2):e73-80. PubMed ID: 22239529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
    Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
    Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
    Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
    Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of hepatitis C virus replication by antimonial compounds.
    Hwang DR; Lin RK; Leu GZ; Lin TY; Lien TW; Yu MC; Yeh CT; Hsu JT
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4197-202. PubMed ID: 16189098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
    Hernandez D; Falk P; Yu F; Zhai G; Quan Y; Faria T; Cao K; Scola P; McPhee F
    Biochem Pharmacol; 2013 Jan; 85(1):21-8. PubMed ID: 23063413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The science of direct-acting antiviral and host-targeted agent therapy.
    Pawlotsky JM
    Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells.
    Fillebeen C; Pantopoulos K
    J Hepatol; 2010 Dec; 53(6):995-9. PubMed ID: 20813419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apigenin restricts FMDV infection and inhibits viral IRES driven translational activity.
    Qian S; Fan W; Qian P; Zhang D; Wei Y; Chen H; Li X
    Viruses; 2015 Mar; 7(4):1613-26. PubMed ID: 25835532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of hepatitis C virus infection by polyoxometalates.
    Qi Y; Xiang Y; Wang J; Qi Y; Li J; Niu J; Zhong J
    Antiviral Res; 2013 Nov; 100(2):392-8. PubMed ID: 24025401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.
    Sandmann L; Wilson M; Back D; Wedemeyer H; Manns MP; Steinmann E; Pietschmann T; von Hahn T; Ciesek S
    Antiviral Res; 2012 Oct; 96(1):51-8. PubMed ID: 22842003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122.
    Kambara H; Fukuhara T; Shiokawa M; Ono C; Ohara Y; Kamitani W; Matsuura Y
    J Virol; 2012 Feb; 86(3):1382-93. PubMed ID: 22114337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus replication-specific inhibition of microRNA activity with self-cleavable allosteric ribozyme.
    Lee CH; Kim JH; Kim HW; Myung H; Lee SW
    Nucleic Acid Ther; 2012 Feb; 22(1):17-29. PubMed ID: 22217271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.
    Nunnari G; Schnell MJ
    Front Biosci (Schol Ed); 2011 Jun; 3(3):1032-7. PubMed ID: 21622252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of HCV replication by serine palmitoyltransferase inhibition.
    Lowe AW; Moseley RH
    Gastroenterology; 2013 Oct; 145(4):701-2. PubMed ID: 24187689
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatitis C Virus Dysregulates Polyamine and Proline Metabolism and Perturbs the Urea Cycle.
    Zakirova NF; Khomich OA; Smirnova OA; Molle J; Duponchel S; Yanvarev DV; Valuev-Elliston VT; Monnier L; Grigorov B; Ivanova ON; Karpenko IL; Golikov MV; Bovet C; Rindlisbacher B; Khomutov AR; Kochetkov SN; Bartosch B; Ivanov AV
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.